Ventricular-assist devices for the treatment of chronic heart failure

References

• Redfield MM. Heart failure – an epidemic of uncertain proportions. N. Engl. J. Med.347(18), 1442–1444 (2002).
   PubMed Web of Science ®Google Scholar
• Miller LW, Missov ED. Epidemiology of heart failure. Cardiol. Clin.19(4), 547–555 (2001).
   PubMedGoogle Scholar
• Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation113(6), e85–e151 (2006).
   PubMed Web of Science ®Google Scholar
• O’Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J. Heart Lung Transplant.13(4), S107–S112 (1994).
   PubMed Web of Science ®Google Scholar
• Mackowiak J. Cost of heart failure to the healthcare system. Am. J. Manag. Care4(Suppl. 6), S338–S342 (1998).
   Google Scholar
• Taylor DO, Edwards LB, Boucek MM et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report – 2006. J. Heart Lung Transplant.25(8), 869–879 (2006).
   PubMed Web of Science ®Google Scholar
• Deng MC, Edwards LB, Hertz MI et al. Mechanical Circulatory Support Device Database of the International Society for Heart and Lung Transplantation: second annual report – 2004. J. Heart Lung Transplant.23(9), 1027–1034 (2004).
   PubMed Web of Science ®Google Scholar
• Navia JL, McCarthy PM, Hoercher KJ et al. Do left ventricular assist device (LVAD) bridge-to-transplantation outcomes predict the results of permanent LVAD implantation? Ann. Thorac. Surg.74(6), 2051–2062 (2002).
   PubMed Web of Science ®Google Scholar
• Sun BC, Catanese KA, Spanier TB et al. 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann. Thorac. Surg.68(2), 688–694 (1999).
   PubMed Web of Science ®Google Scholar
• Frazier OH, Rose EA, Oz MC et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J. Thorac. Cardiovasc. Surg.122(6), 1186–1195 (2001).
   PubMed Web of Science ®Google Scholar
• Renlund DG. Building a bridge to heart transplantation. N. Engl. J. Med.351(9), 849–851 (2004).
   PubMed Web of Science ®Google Scholar
• Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J. Heart Lung Transplant.19(10), 909–931 (2000).
   PubMed Web of Science ®Google Scholar
• Taylor DO, Edwards LB, Boucek MM, Trulock EP, Keck BM, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report – 2004. J. Heart Lung Transplant.23(7), 796–803 (2004).
   PubMed Web of Science ®Google Scholar
• Burton NA, Lefrak EA, Macmanus Q et al. A reliable bridge to cardiac transplantation: the TCI left ventricular assist device. Ann. Thorac. Surg.55(6), 1425–1430 (1993).
   PubMed Web of Science ®Google Scholar
• Copeland JG, Smith RG, Arabia FA et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N. Engl. J. Med.351(9), 859–867 (2004).
   PubMed Web of Science ®Google Scholar
• DeRose JJ Jr, Umana JP, Argenziano M et al. Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery. J. Am. Coll. Cardiol.30(7), 1773–1777 (1997).
   PubMed Web of Science ®Google Scholar
• Drakos SG, Kfoury AG, Long JW et al. Effect of mechanical circulatory support on outcomes after heart transplantation. J. Heart Lung Transplant.25(1), 22–28 (2006).
   PubMed Web of Science ®Google Scholar
• Massad MG, McCarthy PM, Smedira NG et al. Does successful bridging with the implantable left ventricular assist device affect cardiac transplantation outcome? J. Thorac. Cardiovasc. Surg.112(5), 1275–1281 (1996).
   PubMed Web of Science ®Google Scholar
• Mavroidis D, Sun BC, Pae WE Jr. Bridge to transplantation: the Penn State experience. Ann. Thorac. Surg.68(2), 684–687 (1999).
   PubMed Web of Science ®Google Scholar
• Schmid C, Welp H, Klotz S, Baba HA, Wilhelm MJ, Scheld HH. Outcome of patients surviving to heart transplantation after being mechanically bridged for more than 100 days. J. Heart Lung Transplant.22(9), 1054–1058 (2003).
   PubMed Web of Science ®Google Scholar
• Frazier OH, Rose EA, McCarthy P et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann. Surg.222(3), 327–336 (1995).
   PubMed Web of Science ®Google Scholar
• Oz MC, Argenziano M, Catanese KA et al. Bridge experience with long-term implantable left ventricular assist devices. Are they an alternative to transplantation? Circulation95(7), 1844–1852 (1997).
   PubMed Web of Science ®Google Scholar
• Choong CK, Pasque MK, Shelton K et al. The beneficial role of left ventricular assist device destination therapy in the reversal of contraindications to cardiac transplantation. J. Thorac. Cardiovasc. Surg.130(3), 879–880 (2005).
   PubMed Web of Science ®Google Scholar
• Frazier OH, Macris MP, Myers TJ et al. Improved survival after extended bridge to cardiac transplantation. Ann. Thorac. Surg.57(6), 1416–1422 (1994).
   PubMed Web of Science ®Google Scholar
• McKenna DH Jr, Eastlund T, Segall M, Noreen HJ, Park S. HLA alloimmunization in patients requiring ventricular assist device support. J. Heart Lung Transplant.21(11), 1218–1224 (2002).
   PubMed Web of Science ®Google Scholar
• Itescu S, Tung TC, Burke EM et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation98(8), 786–793 (1998).
   PubMedGoogle Scholar
• Smith JD, Danskine AJ, Laylor RM, Rose ML, Yacoub MH. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl. Immunol.1(1), 60–65 (1993).
   PubMedGoogle Scholar
• Mehra MR, Uber PA, Uber WE, Scott RL, Park MH. Allosensitization in heart transplantation: implications and management strategies. Curr. Opin. Cardiol.18(2), 153–158 (2003).
   PubMed Web of Science ®Google Scholar
• Drakos SG, Kfoury AG, Long JW et al. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. Ann. Thorac. Surg.82(3), 889–893 (2006).
   PubMed Web of Science ®Google Scholar
• Rose EA, Gelijns AC, Moskowitz AJ et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N. Engl. J. Med.345(20), 1435–1443 (2001).
   PubMed Web of Science ®Google Scholar
• Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). J. Am. Coll. Cardiol.46(6), e1–e82 (2005).
   PubMed Web of Science ®Google Scholar
• Park SJ, Tector A, Piccioni W et al. Left ventricular assist devices as destination therapy: a new look at survival. J. Thorac. Cardiovasc. Surg.129(1), 9–17 (2005).
   PubMed Web of Science ®Google Scholar
• Long JW, Kfoury AG, Slaughter MS et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest. Heart Fail.11(3), 133–138 (2005).
   PubMedGoogle Scholar
• Dandel M, Weng Y, Siniawski H, Potapov E, Lehmkuhl HB, Hetzer R. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation112(Suppl. 9), I37–I45 (2005).
   PubMed Web of Science ®Google Scholar
• Farrar DJ, Holman WR, McBride LR et al. Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function. J. Heart Lung Transplant.21(5), 516–521 (2002).
   PubMed Web of Science ®Google Scholar
• Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial recovery. Ann. Thorac. Surg.68(2), 734–741 (1999).
   PubMed Web of Science ®Google Scholar
• Gorcsan J 3rd, Severyn D, Murali S, Kormos RL. Non-invasive assessment of myocardial recovery on chronic left ventricular assist device: results associated with successful device removal. J. Heart Lung Transplant.22(12), 1304–1313 (2003).
   PubMed Web of Science ®Google Scholar
• Mancini DM, Beniaminovitz A, Levin H et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation98(22), 2383–2389 (1998).
   PubMed Web of Science ®Google Scholar
• Simon MA, Kormos RL, Murali S et al. Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics, and outcomes. Circulation112(Suppl. 9), I32–I36 (2005).
   PubMed Web of Science ®Google Scholar
• Yacoub MH. A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur. Heart J.22(7), 534–540 (2001).
   PubMed Web of Science ®Google Scholar
• Matsumiya G, Monta O, Fukushima N et al. Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J. Thorac. Cardiovasc. Surg.130(3), 699–704 (2005).
   PubMed Web of Science ®Google Scholar
• Birks EJ, Tansley P, Hardy J et al. Reversal of severe heart failure with left ventricular assist and pharmacologic therapy. N. Engl. J. Med.355(18), 1873–84 (2006).
   PubMed Web of Science ®Google Scholar
• Hall JL, Grindle S, Han X et al. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol. Genomics17(3), 283–291 (2004).
   PubMed Web of Science ®Google Scholar
• Bruggink AH, van Oosterhout MF, de Jonge N et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J. Heart Lung Transplant.25(9), 1091–1098 (2006).
   PubMed Web of Science ®Google Scholar
• Klotz S, Naka Y, Oz MC, Burkhoff D. Biventricular assist device-induced right ventricular reverse structural and functional remodeling. J. Heart Lung Transplant.24(9), 1195–1201 (2005).
   PubMed Web of Science ®Google Scholar
• Birks EJ, Hall JL, Barton PJ et al. Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support. Circulation112(Suppl. 9), I57–I64 (2005).
   PubMed Web of Science ®Google Scholar
• Torre-Amione G, Stetson SJ, Youker KA et al. Decreased expression of tumor necrosis factor-α in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation100(11), 1189–1193 (1999).
   PubMed Web of Science ®Google Scholar
• Kuhn M, Voss M, Mitko D et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. Cardiovasc. Res.64(2), 308–314 (2004).
   PubMed Web of Science ®Google Scholar
• Takeishi Y, Jalili T, Hoit BD et al. Alterations in Ca2+ cycling proteins and G α q signaling after left ventricular assist device support in failing human hearts. Cardiovasc. Res.45(4), 883–888 (2000).
   PubMed Web of Science ®Google Scholar
• Terracciano CM, Hardy J, Birks EJ, Khaghani A, Banner NR, Yacoub MH. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation109(19), 2263–2265 (2004).
   PubMed Web of Science ®Google Scholar
• Ogletree-Hughes ML, Stull LB, Sweet WE, Smedira NG, McCarthy PM, Moravec CS. Mechanical unloading restores β-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation104(8), 881–886 (2001).
   PubMed Web of Science ®Google Scholar
• Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation97(23), 2316–2322 (1998).
   PubMed Web of Science ®Google Scholar
• Hon JK, Yacoub MH. Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann. Thorac. Surg.75(Suppl. 6), S36–S41 (2003).
   PubMedGoogle Scholar
• Young JB. Healing the heart with ventricular assist device therapy: mechanisms of cardiac recovery. Ann. Thorac. Surg.71(Suppl. 3), S210–S219 (2001).
   PubMed Web of Science ®Google Scholar
• Maurice JP, Hata JA, Shah AS et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery. J. Clin. Invest.104(1), 21–29 (1999).
   PubMed Web of Science ®Google Scholar
• Milano CA, Allen LF, Rockman HA et al. Enhanced myocardial function in transgenic mice overexpressing the β 2-adrenergic receptor. Science264(5158), 582–586 (1994).
   PubMed Web of Science ®Google Scholar
• Wong K, Boheler KR, Bishop J, Petrou M, Yacoub MH. Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features. Cardiovasc. Res.37(1), 115–122 (1998).
   PubMed Web of Science ®Google Scholar
• Wong K, Boheler KR, Petrou M, Yacoub MH. Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression. Circulation96(7), 2239–2246 (1997).
   PubMedGoogle Scholar
• Drakos SG, Kfoury AG, Gilbert EM et al. Multivariate predictors of heart transplantation outcomes in the era of chronic mechanical circulatory support. Ann. Thorac. Surg.83(1), 62–67 (2007).
   PubMed Web of Science ®Google Scholar
• Lietz K, Miller LW. Left ventricular assist devices: evolving devices and indications for use in ischemic heart disease. Curr. Opin. Cardiol.19(6), 613–618 (2004).
   PubMed Web of Science ®Google Scholar
• Topkara VK, Dang NC, Barili F et al. Predictors and outcomes of continuous veno-venous hemodialysis use after implantation of a left ventricular assist device. J. Heart Lung Transplant.25(4), 404–408 (2006).
   PubMed Web of Science ®Google Scholar
• Smith GL, Vaccarino V, Kosiborod M et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J. Card. Fail.9(1), 13–25 (2003).
   PubMed Web of Science ®Google Scholar
• Dang NC, Topkara VK, Mercando M et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J. Heart Lung Transplant.25(1), 1–6 (2006).
   PubMed Web of Science ®Google Scholar
• Ochiai Y, McCarthy PM, Smedira NG et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation106(12 Suppl. 1), I198–I202 (2002).
   PubMed Web of Science ®Google Scholar
• Fukamachi K, McCarthy PM, Smedira NG, Vargo RL, Starling RC, Young JB. Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann. Thorac. Surg.68(6), 2181–2184 (1999).
   PubMed Web of Science ®Google Scholar
• Rao V, Oz MC, Flannery MA, Catanese KA, Argenziano M, Naka Y. Revised screening scale to predict survival after insertion of a left ventricular assist device. J. Thorac. Cardiovasc. Surg.125(4), 855–862 (2003).
   PubMed Web of Science ®Google Scholar
• Holdy K, Dembitsky W, Eaton LL et al. Nutrition assessment and management of left ventricular assist device patients. J. Heart Lung Transplant.24(10), 1690–1696 (2005).
   PubMed Web of Science ®Google Scholar
• Lietz K, JW L, AG K et al. Risk score to predict survival to hospital discharge after left-ventricular assist device (LVAD) implantation as destination therapy (DT). J. Heart Lung Transplant.12(6 Suppl. 1), S4 (2006).
   Google Scholar
• Miller LW. Oral presentation at the 10th Annual Scientific Meeting of the Heart Failure Society of America, Seattle, WA, USA 10–13 September 2006.
   Google Scholar
• Baddour LM, Bettmann MA, Bolger AF et al. Nonvalvular cardiovascular device-related infections. Circulation108(16), 2015–2031 (2003).
   PubMed Web of Science ®Google Scholar
• Deng MC, Loebe M, El-Banayosy A et al. Mechanical circulatory support for advanced heart failure: effect of patient selection on outcome. Circulation103(2), 231–237 (2001).
   PubMed Web of Science ®Google Scholar
• Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. Lancet Infect. Dis.6(7), 426–437 (2006).
   PubMed Web of Science ®Google Scholar
• Torre-Amione G. Immune activation in chronic heart failure. Am. J. Cardiol.95(11A), 3C–8C (2005).
   PubMed Web of Science ®Google Scholar
• Itescu S, John R. Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications. Ann. Thorac. Surg.75(Suppl. 6), S58–S65 (2003).
   Google Scholar
• Dembitsky WP, Tector AJ, Park S et al. Left ventricular assist device performance with long-term circulatory support: lessons from the REMATCH trial. Ann. Thorac. Surg.78(6), 2123–2129 (2004).
   PubMed Web of Science ®Google Scholar
• Chinn R, Dembitsky W, Eaton L et al. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J.51(4), 461–470 (2005).
   PubMed Web of Science ®Google Scholar
• Dowling RD, Park SJ, Pagani FD et al. HeartMate VE LVAS design enhancements and its impact on device reliability. Eur. J. Cardiothorac. Surg.25(6), 958–963 (2004).
   PubMed Web of Science ®Google Scholar
• Potapov EV, Weng Y, Drews T, Jurmann M, Hetzer R. Longest time of support by the Novacor left ventricular assist device without pump exchange. Ann. Thorac. Surg.80(6), 2421 (2005).
   PubMed Web of Science ®Google Scholar
• Westaby S, Frazier OH, Banning A. Six years of continuous mechanical circulatory support. N. Engl. J. Med.355(3), 325–327 (2006).
   PubMed Web of Science ®Google Scholar
• Lazar RM, Shapiro PA, Jaski BE et al. Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart failure (REMATCH) experience. Circulation109(20), 2423–2427 (2004).
   PubMed Web of Science ®Google Scholar
• Schmid C, Weyand M, Nabavi DG et al. Cerebral and systemic embolization during left ventricular support with the Novacor N100 device. Ann. Thorac. Surg.65(6), 1703–1710 (1998).
   PubMed Web of Science ®Google Scholar
• Strauch JT, Spielvogel D, Haldenwang PL et al. Recent improvements in outcome with the Novacor left ventricular assist device. J. Heart Lung Transplant.22(6), 674–680 (2003).
   PubMed Web of Science ®Google Scholar
• Czer LS, Matloff JM, Chaux A, De Robertis M, Stewart ME, Gray RJ. The St. Jude valve: analysis of thromboembolism, warfarin-related hemorrhage, and survival. Am. Heart J.114(2), 389–397 (1987).
   PubMed Web of Science ®Google Scholar
• Hartz RS, LoCicero J 3rd, Kucich V et al. Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve in the aortic position. J. Thorac. Cardiovasc. Surg.92(4), 684–690 (1986).
   PubMed Web of Science ®Google Scholar
• No authors listed. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med.154(13), 1449–1457 (1994).
   PubMed Web of Science ®Google Scholar
• Petrucci R, Kushon D, Inkles R, Fitzpatrick J, Twomey C, Samuels L. Cardiac ventricular support. Considerations for psychiatry. Psychosomatics40(4), 298–303 (1999).
   PubMed Web of Science ®Google Scholar
• Casida J. The lived experience of spouses of patients with a left ventricular assist device before heart transplantation. Am. J. Crit. Care14(2), 145–151 (2005).
   PubMed Web of Science ®Google Scholar
• Oz MC, Gelijns AC, Miller L et al. Left ventricular assist devices as permanent heart failure therapy: the price of progress. Ann. Surg.238(4), 577–583 (2003).
   PubMed Web of Science ®Google Scholar
• Showstack J, Katz PP, Lake JR et al. Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA281(15), 1381–1386 (1999).
   PubMed Web of Science ®Google Scholar
• Digiorgi PL, Reel MS, Thornton B, Burton E, Naka Y, Oz MC. Heart transplant and left ventricular assist device costs. J. Heart Lung Transplant.24(2), 200–204 (2005).
   PubMed Web of Science ®Google Scholar
• Miller LW, Nelson KE, Bostic RR, Tong K, Slaughter MS, Long JW. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post-REMATCH era. J. Heart Lung Transplant.25(7), 778–784 (2006).
   PubMed Web of Science ®Google Scholar
• Song X, Throckmorton AL, Untaroiu A et al. Axial flow blood pumps. ASAIO J.49(4), 355–364 (2003).
   PubMed Web of Science ®Google Scholar
• Frazier OH. Implantation of the Jarvik 2000 left ventricular assist device without the use of cardiopulmonary bypass. Ann. Thorac. Surg.75(3), 1028–1030 (2003).
   PubMed Web of Science ®Google Scholar
• Jett GK. Physiology of nonpulsatile circulation: acute versus chronic support. ASAIO J.45(3), 119–122 (1999).
   PubMed Web of Science ®Google Scholar
• Saito S, Westaby S, Piggot D et al. End-organ function during chronic nonpulsatile circulation. Ann. Thorac. Surg.74(4), 1080–1085 (2002).
   PubMed Web of Science ®Google Scholar
• Terrovitis JV, Charitos CE, Tsolakis EJ et al. Superior performance of a paraaortic counterpulsation device compared to the intraaortic balloon pump. World J. Surg.27(12), 1311–1316 (2003).
   PubMed Web of Science ®Google Scholar
• Nanas JN, Nanas SN, Charitos CE et al. Effectiveness of a counterpulsation device implanted on the ascending aorta. ASAIO Trans.33(3), 203–206 (1987).
   PubMedGoogle Scholar
• Charitos CE, Nanas JN, Kontoyiannis DA et al. The efficacy of the high volume counterpulsation technique at very low levels of aortic pressure. J. Cardiovasc. Surg. (Torino)39(5), 625–632 (1998).
   PubMed Web of Science ®Google Scholar
• Nanas JN, Lolas CT, Charitos CE et al. A valveless high stroke volume counterpulsation device restores hemodynamics in patients with congestive heart failure and intractable cardiogenic shock awaiting heart transplantation. J. Thorac. Cardiovasc. Surg.111(1), 55–61 (1996).
   PubMed Web of Science ®Google Scholar
• Nanas JN, Mason JW, Riebman JB, Charitos CE, Burns GL, Olsen DB. Preclinical evaluation of the abdominal aortic counterpulsation device. Am. Heart J.116(4), 1003–1008 (1988).
   PubMed Web of Science ®Google Scholar
• Nanas JN, Nanas SN, Charitos CE et al. Hemodynamic effects of a counterpulsation device implanted on the ascending aorta in severe cardiogenic shock. ASAIO Trans.34(3), 229–234 (1988).
   PubMedGoogle Scholar
• Stamatelopoulos SF, Nanas JN, Saridakis NS et al. Treating severe cardiogenic shock by large counterpulsation volumes. Ann. Thorac. Surg.62(4), 1110–1117 (1996).
   PubMed Web of Science ®Google Scholar
• Drakos SG, Charitos CE, Ntalianis A et al. Comparison of pulsatile with nonpulsatile mechanical support in a porcine model of profound cardiogenic shock. ASAIO J.51(1), 26–29 (2005).
   PubMed Web of Science ®Google Scholar
• Wakisaka Y, Taenaka Y, Chikanari K et al. Long-term evaluation of a nonpulsatile mechanical circulatory support system. Artif. Organs21(7), 639–644 (1997).
   PubMed Web of Science ®Google Scholar
• Letsou GV, Myers TJ, Gregoric ID et al. Continuous axial-flow left ventricular assist device (Jarvik 2000) maintains kidney and liver perfusion for up to 6 months. Ann. Thorac. Surg.76(4), 1167–1170 (2003).
   PubMed Web of Science ®Google Scholar
• Lietz K, Long J, Kfoury AG et al. Risk score to predict survival to hospital discharge after left ventricular assist device implantation as destination therapy. J. Card. Fail.12(6), (2006) (Abstract 10).
   Google Scholar